Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $86.60B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 1.91M
Average 1.68M
ELV Pre-Tax Margin
Income before tax as a percentage of revenue.
Elevance Health Inc.NYSE: ELV
Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026
Pre-tax margin widens to 3.5%
Pre-tax margin was 3.5% in Q3 FY2026, up 0.7 pp from a year earlier. On a trailing-twelve-month basis it was 3.1%, down 0.5 pp year over year. Over 3 fiscal years it narrowed by 1.5 pp.
Context
- Pre-tax margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 3.4%
- Year-over-year change
- -1.1pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.4% | -1.1pp |
| FY2024 | 2024-12-31 | 4.5% | -0.0pp |
| FY2023 | 2023-12-31 | 4.5% | -0.4pp |
| FY2022 | 2022-12-31 | 4.9% | -0.9pp |
| FY2021 | 2021-12-31 | 5.7% | — |
Pre-Tax Margin vs competitors
How ELV compares with its peers on the latest reported figures
- ELV's LTM Sep 2026 pre-tax margin of 3.1% is the 3rd highest of the 9 companies compared; the peer median is 1.3%.
- Its year-over-year change of -0.5 pp is the 6th highest of 9, against a peer median of -0.2 pp.
- Over three fiscal years its change of -1.5 pp compares with a peer median of -2.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 4.4% | -0.7 pp | -4.8 pp | |
| LTM Jun 2026 | 3.9% | +5.3 pp | +11.1 pp | |
| LTM Sep 2026 | 3.1% | -0.5 pp | -1.5 pp | |
| LTM Sep 2026 | 2.9% | -0.1 pp | -1.9 pp | |
| LTM Jun 2026 | 1.4% | -0.3 pp | -1.3 pp | |
| LTM Sep 2026 | 1.1% | -0.1 pp | -2.7 pp | |
| LTM Mar 2026 | 0.5% | +3.5 pp | +10.4 pp | |
| LTM Sep 2026 | -0.1% | -2.7 pp | -2.0 pp | |
| LTM Jun 2026 | -2.4% | -3.9 pp | -4.8 pp | |
| Peer median (excluding ELV) | 1.3% | -0.2 pp | -2.0 pp | |
Competitors are the stored peer set for ELV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 138.64B | 156.6B | 171.34B | 176.81B | 199.13B |
| Cost of Revenue | 102.65B | 116.64B | 124.33B | 127.57B | 148.22B |
| Gross Profit | 35.99B | 39.95B | 47.01B | 49.24B | 50.9B |
| Gross Margin | 26.0% | 25.5% | 27.4% | 27.9% | 25.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 27.05B | 31.5B | 38.27B | 40.36B | 42.79B |
| Depreciation & Amortization | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B |
| EBITDA | 10.03B | 10.13B | 10.49B | 10.48B | 9.66B |
| EBITDA Margin | 7.2% | 6.5% | 6.1% | 5.9% | 4.9% |
| Operating Income | 8.95B | 8.45B | 8.75B | 8.89B | 8.11B |
| Operating Margin | 6.5% | 5.4% | 5.1% | 5.0% | 4.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 798M | 851M | 1.03B | 1.19B | 1.4B |
| Other Income / Expenses | (1.02B) | (851M) | (1.03B) | (984M) | (1.4B) |
| Income Before Tax | 7.93B | 7.6B | 7.72B | 7.9B | 6.71B |
| Pre-Tax Margin | 5.7% | 4.9% | 4.5% | 4.5% | 3.4% |
| Income Tax Expense | 1.83B | 1.71B | 1.72B | 1.93B | 1.05B |
| Net Income | 6.1B | 5.89B | 5.99B | 5.98B | 5.66B |
| Net Margin | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% |
| EPS (Basic) | 25.25 | 24.56 | 25.38 | 25.81 | 25.18 |
| EPS (Diluted) | 24.73 | 24.28 | 25.22 | 25.68 | 25.12 |
| Weighted Avg Shares | 243.8M | 240M | 233.07M | 232.87M | 221.8M |
| Weighted Avg Shares (Diluted) | 246.8M | 242.8M | 237.4M | 232.9M | 221.8M |
Elevance Health Inc.
NYSE:ELV
Intrinsic Alpha fair value
Locked
Current Price
$400.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.